Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Vaccines01:21

Vaccines

42
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...
42
Vaccinations01:51

Vaccinations

53.8K
Overview
53.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physician Perspectives on the Transition to Primary Human Papillomavirus Testing for Cervical Cancer Screening.

Journal of lower genital tract disease·2026
Same author

Nonavalent HPV vaccine to prevent recurrent anal or vulvar high-grade squamous intraepithelial lesions (VIVA trial): A randomized, double-blind, placebo-controlled trial.

International journal of cancer·2026
Same author

Feasibility of a mobile health platform for patient education and remote symptom monitoring in patients with advanced ovarian cancer undergoing primary chemotherapy.

Gynecologic oncology·2026
Same author

A randomized pilot study of HPV16 L2E7E6 fusion protein vaccination site post-treatment for HPV16+ cervical cancer.

Gynecologic oncology·2025
Same author

The use of transrectal ultrasound to improve gynecologic interstitial applicator implantation.

Gynecologic oncology·2025
Same author

Self-Collection for Human Papillomavirus Testing in Clinical Settings: An Opportunity to Reflect on the Disconnect Between Guidelines and Clinical Practice.

Obstetrics and gynecology·2025

Related Experiment Video

Updated: Mar 31, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

13.1K

HPV vaccines: Translating immunogenicity into efficacy.

Taylor B Turner1, Warner K Huh1

  • 1a Division of Gynecologic Oncology, Department of Obstetrics and Gynecology , University of Alabama at Birmingham , Birmingham , AL , USA.

Human Vaccines & Immunotherapeutics
|October 30, 2015
PubMed
Summary

Human papillomavirus (HPV) vaccines are highly effective, but a specific immune marker, or correlate, for vaccine response remains elusive. Further research is needed to understand HPV vaccine immunity beyond antibody levels.

Keywords:
Human papilloma virus vaccineimmune correlate

More Related Videos

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions
13:56

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions

Published on: July 18, 2013

11.7K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

23.0K

Related Experiment Videos

Last Updated: Mar 31, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

13.1K
A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions
13:56

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions

Published on: July 18, 2013

11.7K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

23.0K

Area of Science:

  • Immunology
  • Vaccinology
  • Oncology

Background:

  • Current human papillomavirus (HPV) vaccines demonstrate high efficacy in preventing persistent infections and precancerous cervical lesions.
  • The unique immunogenicity of HPV and vaccine effectiveness have hindered the identification of a specific immune correlate for HPV vaccination.
  • Existing methods measuring vaccine response via serum neutralizing antibodies lack verified correlation and do not fully explain protection against non-mucosal HPV-related lesions.

Purpose of the Study:

  • To highlight the challenge in identifying a definitive immune correlate for human papillomavirus (HPV) vaccination.
  • To discuss the limitations of current immune response measures, such as serum neutralizing antibodies, in explaining vaccine efficacy.
  • To emphasize the need for identifying a true correlate to advance future HPV vaccine research.

Main Methods:

  • Review of existing literature on HPV vaccine immunogenicity and efficacy.
  • Analysis of the limitations of serum neutralizing antibodies as an immune correlate.
  • Discussion of the complexities in identifying correlates for highly efficacious vaccines.

Main Results:

  • No definitive immune correlate has been identified for current HPV vaccines despite their high efficacy.
  • Serum neutralizing antibodies, while used to measure response, are not a verified correlate and do not explain all aspects of protection.
  • The high success rate of HPV vaccines complicates efforts to identify underlying immune correlates.

Conclusions:

  • Identifying a true immune correlate for HPV vaccination is challenging due to the vaccine's high efficacy and unique immunogenicity.
  • Current understanding of HPV vaccine response is incomplete, as antibody levels do not fully account for observed protection.
  • Further investigation is crucial for understanding the immunological mechanisms underlying HPV vaccine effectiveness and for developing future vaccines.